Skip to content

Vir Biotechnology

US · VIR #2824 by market cap Listed 2019
8.39 -0.48 -5.41%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 8.77 -1.13%
After-hours 8.30 -1.05%
13.658.258.392026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on VIR?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +21.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 100.0% Better than 99%
Operating margin -720.9% Better than 3%
Net margin -658.4% Better than 3%
Return on equity -45.7% Better than 10%
Return on invested capital -44.3% Better than 7%
Momentum B-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -14.2% Better than 41%
6-month return -8.7% Better than 42%
12-month return (ex latest month) 86.1% Better than 94%
Distance below 52-week high 41.7% Better than 27%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 5.5x Better than 88%
Debt to assets 9.8% Better than 70%
Free cash flow / net income 309.2% Better than 86%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 167.3% Better than 92%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -15.76%
1M -21.88%
3M -8.90%
6M -5.52%
YTD +39.14%
1Y +50.90%
3Y -14.39%
5Y -74.38%

Key statistics

Price & volume

Prev close
8.87
Open
8.77
Day range
8.34 - 8.92
Avg price
8.55
Volume
3.09M
Turnover
26.40M
Amplitude
6.48%
52-week range
5.45 - 14.38

Valuation

P/E
-2.66
P/E (TTM)
-7.11
P/B
1.74
EPS
-3.16
Net profit
-588.62M
Net assets
895.96M

Share structure

Market cap
1.56B
Float cap
1.31B
Shares out
186.27M
Float shares
156.08M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2019-10-11
52-week range 33% of range
5.45 14.38

41.7% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-8.37M net over the window

Short interest

Shares short
16.87M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Vir Biotechnology (VIR)?

Vir Biotechnology last traded at 8.39. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Vir Biotechnology's market cap?

About 1.56B.

What is the P/E ratio of Vir Biotechnology?

The trailing twelve-month P/E is -7.11. The Valuation tab shows it against the stock's own five-year range.

Does Vir Biotechnology pay a dividend?

Vir Biotechnology does not currently pay a regular dividend.

Is Vir Biotechnology a buy according to analysts?

The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 22.43, which implies 167.3% upside from the current price. This is not investment advice.

What is Vir Biotechnology's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Vir Biotechnology a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Vir Biotechnology discussion 0 comments

Add a comment